Enveric Biosciences, Inc.
ENVB
$1.64
$0.042.19%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 25.24% | 30.44% | 10.09% | -34.04% | 11.07% |
| Total Depreciation and Amortization | -54.07% | -52.12% | -52.36% | -52.83% | -5.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -43.39% | -69.47% | -84.25% | -41.23% | -42.05% |
| Change in Net Operating Assets | -60.56% | -88.59% | -142.74% | 126.48% | 14.01% |
| Cash from Operations | 5.64% | -36.10% | -123.82% | 34.58% | 7.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -43.73% | 455.83% | 477.91% | 596.28% | -10.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -43.73% | 480.30% | 478.02% | 1,205.52% | -33.18% |
| Foreign Exchange rate Adjustments | -287.18% | 169.03% | -151.89% | -376.92% | -148.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -88.74% | 205.65% | 332.23% | 49.37% | -49.52% |